Last reviewed · How we verify
Venous thromboembolic events
Approved treatments
- Dabigatran Etexilate · Boehringer Ingelheim
Dabigatran works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process. - Dabigatran Etexilate · Boehringer Ingelheim
Dabigatran works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Venous thromboembolic events patent landscape — cliff calendar, originator estates, attackable patents
- Venous thromboembolic events treatment landscape brief
- Venous thromboembolic events treatment updates RSS
Frequently asked questions about Venous thromboembolic events
What drugs treat Venous thromboembolic events?
Tracked treatments include Dabigatran Etexilate.
What is the treatment for Venous thromboembolic events?
Standard treatment for Venous thromboembolic events includes Dabigatran Etexilate. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Venous thromboembolic events patent cliff · Venous thromboembolic events CI report
- Treatment: Dabigatran Etexilate · Boehringer Ingelheim
- Treatment: Dabigatran Etexilate · Boehringer Ingelheim
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing